[go: up one dir, main page]

BRPI0607529B8 - compostos azol e composições farmacêuticas compreendendo os mesmos - Google Patents

compostos azol e composições farmacêuticas compreendendo os mesmos

Info

Publication number
BRPI0607529B8
BRPI0607529B8 BRPI0607529A BRPI0607529A BRPI0607529B8 BR PI0607529 B8 BRPI0607529 B8 BR PI0607529B8 BR PI0607529 A BRPI0607529 A BR PI0607529A BR PI0607529 A BRPI0607529 A BR PI0607529A BR PI0607529 B8 BRPI0607529 B8 BR PI0607529B8
Authority
BR
Brazil
Prior art keywords
azole compounds
same
pharmaceutical compositions
stroke
compounds
Prior art date
Application number
BRPI0607529A
Other languages
English (en)
Inventor
Ku Bon-Chul
Kim Choon-Gil
Im Dae-Joong
Lee Eun-Ho
Yi Han-Ju
Lee Hyun-Seok
Moon Choi Yong
Kang Young-Sun
Shin Yu-Jin
Original Assignee
Sk Biopharmaceuticals Co Ltd
Sk Holdings Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37115369&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0607529(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sk Biopharmaceuticals Co Ltd, Sk Holdings Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of BRPI0607529A2 publication Critical patent/BRPI0607529A2/pt
Publication of BRPI0607529B1 publication Critical patent/BRPI0607529B1/pt
Publication of BRPI0607529B8 publication Critical patent/BRPI0607529B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

compostos de azol neuroterapêuticos. compostos de azol contendo grupo carbamoila e sais farmaceuticamente aceitáveis dos mesmos são descritos. os compostos são anticonvulsivos eficazes que são usados no tratamento de distúrbios do sistema nervoso central, especialmente como ansiedade, depressão, convulsão, epilepsia, hemicrânia, distúrbio bipolar, abuso de droga, fumo, adhd, obesidade, distúrbio do sono, dor neuropática, acidente vascular cerebral, dano cognitivo, neurodegeneração, acidente vascular cerebral e espasmo muscular.
BRPI0607529A 2005-04-22 2006-04-21 compostos azol e composições farmacêuticas compreendendo os mesmos BRPI0607529B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67453005P 2005-04-22 2005-04-22
US60/674,530 2005-04-22
PCT/KR2006/001523 WO2006112685A1 (en) 2005-04-22 2006-04-21 Neurotherapeutic azole compounds

Publications (3)

Publication Number Publication Date
BRPI0607529A2 BRPI0607529A2 (pt) 2009-09-15
BRPI0607529B1 BRPI0607529B1 (pt) 2021-05-18
BRPI0607529B8 true BRPI0607529B8 (pt) 2021-05-25

Family

ID=37115369

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607529A BRPI0607529B8 (pt) 2005-04-22 2006-04-21 compostos azol e composições farmacêuticas compreendendo os mesmos

Country Status (21)

Country Link
US (1) US7598279B2 (pt)
EP (1) EP1879873B1 (pt)
JP (1) JP5035238B2 (pt)
KR (1) KR101286499B1 (pt)
CN (1) CN101228138B (pt)
AR (1) AR053065A1 (pt)
AU (1) AU2006237798B2 (pt)
BR (1) BRPI0607529B8 (pt)
CA (1) CA2606258C (pt)
DK (1) DK1879873T3 (pt)
ES (1) ES2441765T3 (pt)
FI (1) FIC20210018I1 (pt)
MX (1) MX2007013197A (pt)
MY (1) MY148589A (pt)
NL (1) NL301106I2 (pt)
PL (1) PL1879873T3 (pt)
PT (1) PT1879873E (pt)
RU (1) RU2418792C2 (pt)
TW (1) TWI398249B (pt)
WO (1) WO2006112685A1 (pt)
ZA (1) ZA200709994B (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
DK2155736T3 (da) * 2007-05-14 2012-03-12 Sk Biopharmaceuticals Co Ltd Ny carbamoyloxyarylalkanoylarylpiperazin- forbindelse, farmaceutiske sammensætninger, omfattende forbindelsen og fremgangsmåde til behandling af smerte, angst og depression ved indgivelse af forbindelsen
CN101808987A (zh) 2007-06-05 2010-08-18 Nsab神经研究瑞典公司分公司 作为皮层儿茶酚胺能神经传递调节剂的二取代的苯基吡咯烷
KR101603487B1 (ko) * 2008-06-05 2016-03-17 에스케이바이오팜 주식회사 3-치환된 프로판아민 화합물
ES2541590T3 (es) * 2009-06-22 2015-07-22 Sk Biopharmaceuticals Co., Ltd. Método para la preparación de éster (R)-1-aril-2-tetrazolil-etílico de ácido carbámico
US8404461B2 (en) * 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
MX350745B (es) 2009-11-06 2017-09-14 Sk Biopharmaceuticals Co Ltd * El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
MX2012005258A (es) 2009-11-06 2012-06-19 Sk Biopharmaceuticals Co Ltd El uso de un compuesto de carbamoilo para el tratamiento del trastorno de deficit de atencion/hiperactividad.
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
CN107011229B (zh) * 2012-01-06 2019-11-05 诺华股份有限公司 杂环化合物和它们的使用方法
US9630896B2 (en) 2013-11-22 2017-04-25 Tansna Therapeutics, Inc. 2,5-dialkyl-4-H/halo/ether-phenol compounds
TWI655179B (zh) * 2014-02-28 2019-04-01 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
ITUA20161941A1 (it) * 2016-03-23 2017-09-23 Univ Degli Studi Di Siena Uso di derivati dell’acido 2-amminotiofen-3- carbossilico per il trattamento delle dipendenze da cibo
KR102489052B1 (ko) * 2016-05-19 2023-01-16 에스케이바이오팜 주식회사 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
KR102421013B1 (ko) * 2016-05-19 2022-07-14 에스케이바이오팜 주식회사 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
KR102421006B1 (ko) * 2016-05-19 2022-07-14 에스케이바이오팜 주식회사 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도
US11571410B2 (en) * 2016-12-14 2023-02-07 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
CN110475544B (zh) * 2016-12-14 2024-03-01 爱思开生物制药株式会社 包含氨基甲酸酯化合物的口腔崩解片
AU2017374459B2 (en) * 2016-12-14 2023-04-27 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for preventing, alleviating, or treating tremors or tremor syndrome
US11147798B2 (en) 2016-12-14 2021-10-19 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for prevention, alleviation, or treatment of demyelinating disease
KR102635931B1 (ko) * 2016-12-14 2024-02-13 에스케이바이오팜 주식회사 가려움증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
DK3556349T3 (da) * 2016-12-14 2022-01-03 Sk Biopharmaceuticals Co Ltd Parenteralt flydende præparat omfattende en carbamatforbindelse
US11389429B2 (en) 2017-11-14 2022-07-19 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for preventing, alleviating or treating myotonia
CN111432813B (zh) 2017-11-14 2024-01-09 爱思开生物制药株式会社 用于预防、减轻、或治疗精神分裂症的包含氨基甲酸酯化合物的共混物
KR102739580B1 (ko) * 2017-11-14 2024-12-06 에스케이바이오팜 주식회사 후기 나트륨 전류의 증가와 관련된 질환을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
KR20200074156A (ko) * 2017-11-14 2020-06-24 에스케이바이오팜 주식회사 내장통 또는 내장 질환에서 기인한 통증을 예방, 경감 또는 치료하기 위한 카바메이트 화합물의 용도
US20200352907A1 (en) 2017-11-14 2020-11-12 Sk Biopharmaceuticals Co., Ltd. Use Of Carbamate Compound For Preventing, Alleviating Or Treating Absence Seizure Or Epilepsy Showing Absence Seizure
US20200268711A1 (en) 2017-11-14 2020-08-27 Sk Biopharmaceuticals Co., Ltd. Use Of Carbamate Compound For Reducing Or Treating Developmental Disorders Including Fragile X Syndrome, Angelman Syndrome Or Rett Syndrome
PL3854391T3 (pl) 2018-09-21 2024-06-24 Sk Biopharmaceuticals Co., Ltd. Związek karbaminianowy i zastosowanie preparatu zawierającego ten związek do zapobiegania, łagodzenia lub leczenia ostrego zaburzenia stresowego lub zespołu stresu pourazowego
TWI826531B (zh) * 2018-09-21 2023-12-21 南韓商愛思開生物製藥股份有限公司 具有㗁二唑之化合物及包含該化合物之醫藥組合物
EP3854392A4 (en) * 2018-09-21 2022-08-17 SK Biopharmaceuticals Co., Ltd. USE OF A CARBAMATE COMPOUND TO PREVENT, RELIEVE OR TREAT CONJUNCTING SEIGES
EP3868375A4 (en) * 2018-10-19 2022-06-29 SK Biopharmaceuticals Co., Ltd. Use of carbamate compound for preventing, alleviating or treating diabetic peripheral neuropathy or chemotherapy-induced peripheral neuropathy
US10611737B1 (en) 2019-10-24 2020-04-07 Sk Biopharmaceuticals Co., Ltd. Method for preparing aryl 2-tetrazol-2-yl ketone with improved selectivity
EP4062906A4 (en) * 2019-11-22 2024-01-03 SK Biopharmaceuticals Co., Ltd. ORAL PHARMACEUTICAL COMPOSITION COMPRISING A CARBAMATE COMPOUND AND METHOD FOR PREPARING THIS COMPOSITION
CN116322641A (zh) 2020-08-06 2023-06-23 爱思开生物制药株式会社 包含氨基甲酸酯化合物的固体口服组合物及其制备方法
CN114317620B (zh) * 2020-09-29 2024-02-02 上海医药工业研究院 一种(r)-2-(2-氯苯基)环氧乙烷的生物制备方法
AR125970A1 (es) 2021-05-28 2023-08-30 Sk Biopharmaceuticals Co Ltd Formulaciones de suspensión acuosa para administración oral que comprenden un compuesto de carbamato
CN115974799B (zh) * 2021-10-14 2024-08-13 成都百裕制药股份有限公司 氨基甲酸酯取代的醇衍生物及其在医药上的应用
ES2931000B2 (es) * 2022-07-14 2023-07-07 Univ Madrid Complutense Proceso para la preparación de cenobamato
CN115716810A (zh) * 2022-11-15 2023-02-28 江苏艾立康医药科技有限公司 一种西诺氨酯的晶体形式及其制备方法
CN118239901A (zh) * 2023-03-15 2024-06-25 江苏恩华药业股份有限公司 一种氨基甲酸(r)-1-(2-氯苯基)-2-四唑-2-基乙酯的晶体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415840A (en) * 1965-10-22 1968-12-10 American Home Prod Pyrazole-1-ethanol derivatives
DK181988A (da) * 1988-03-30 1989-10-01 Dumex Ltd As Thiocarbamidsyreester til brug som terapeutikum samt praeparat til behandling af alkoholmisbrug
JP3113678B2 (ja) * 1991-08-22 2000-12-04 ワーナー−ランバート・コンパニー アミドテトラゾールａｃａｔ阻害剤
KR100912521B1 (ko) * 2001-06-25 2009-08-18 에스케이 주식회사 2-헤테로시클릭-1,2-에탄디올의 카바메이트
US6770659B2 (en) * 2002-08-26 2004-08-03 Sk Corporation Benzoyl piperidine compounds
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds

Also Published As

Publication number Publication date
EP1879873A4 (en) 2011-06-15
BRPI0607529A2 (pt) 2009-09-15
PL1879873T3 (pl) 2014-03-31
TWI398249B (zh) 2013-06-11
JP5035238B2 (ja) 2012-09-26
KR20080005437A (ko) 2008-01-11
TW200722085A (en) 2007-06-16
NL301106I1 (nl) 2021-06-02
WO2006112685A1 (en) 2006-10-26
EP1879873B1 (en) 2013-10-09
AR053065A1 (es) 2007-04-18
FIC20210018I1 (fi) 2021-06-14
US20060258718A1 (en) 2006-11-16
JP2008538557A (ja) 2008-10-30
ZA200709994B (en) 2008-11-26
PT1879873E (pt) 2014-01-03
EP1879873A1 (en) 2008-01-23
NL301106I2 (nl) 2021-08-03
BRPI0607529B1 (pt) 2021-05-18
AU2006237798B2 (en) 2012-07-12
CA2606258A1 (en) 2006-10-26
RU2007143073A (ru) 2009-05-27
ES2441765T3 (es) 2014-02-06
MX2007013197A (es) 2008-02-12
CN101228138A (zh) 2008-07-23
RU2418792C2 (ru) 2011-05-20
US7598279B2 (en) 2009-10-06
MY148589A (en) 2013-05-15
AU2006237798A1 (en) 2006-10-26
CA2606258C (en) 2014-01-14
CN101228138B (zh) 2012-11-21
DK1879873T3 (da) 2013-12-09
KR101286499B1 (ko) 2013-07-16

Similar Documents

Publication Publication Date Title
BRPI0607529B8 (pt) compostos azol e composições farmacêuticas compreendendo os mesmos
WO2009035473A3 (en) Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
BRPI0918868B8 (pt) compostos moduladores do receptor de nmda e composições compreendendo os mesmos
WO2007137247A3 (en) Treatment for depressive disorders
WO2008021113A3 (en) Transdermal methods and systems for treating alzheimer's disease
BR112014009851A2 (pt) moduladores de receptor de nmda e usos dos mesmos
WO2007025286A3 (en) Therapy procedure for drug delivery for trigeminal pain
MX2011001384A (es) Composiciones y metodos para tratar trastornos psiquiatricos.
CL2008002246A1 (es) Uso de compuestos derivados de benzamida para tratar trastornos del sistema nervioso central seleccionados entre depresion, ansiedad trastornos psicoticos, trastornos neurologicos, epilepsia, trastornos cardiovasculares, diabetes, dislipidemias, entre otros; compuestos derivados de benzamida; composicion farmaceutica; y uso de la composicion.
CL2011000043A1 (es) Compuestos derivados de benzoazepina sustituidos; compuestosintermediarios; metodo de sintesis; composicion farmaceutica; y uso en el tratamiento o prevencion de un trastorno del sistema nervioso central.
DK1656122T4 (da) Transdermale lægemiddeltilberedninger med kombinationer af aktive stoffer til behandling af Parkinsons syge
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
UA110199C2 (xx) Тверда дисперсія рифаксиміну
TW200716204A (en) Pharmaceutical composition
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
UA96447C2 (ru) Полиморфные формы (2s)-(4e)-n-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина для лечения расстройств центральной нервной системы
BRPI0515528A (pt) n-metil hidroxietilamina úteis no tratamento de condições do sistema nervoso central
EP4086249A3 (en) 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
ATE507214T1 (de) Neuartige serotonin-wiederaufnahmehemmer als arzneimittel mit peripheriesystem-beschränkter aktivität
BRPI0410837A (pt) composto, composição farmacêutica, e, método para tratar ou prevenir uma doença ou condição
PE20011049A1 (es) Combinacion de farmacos para el tratamiento de la depresion y trastornos relacionados que comprenden mirtazapina
ATE445633T1 (de) Die regeneration von neuronen des zentralen nervensystems stimulierende peptidsubstanz, darauf basierende pharmazeutische zusammensetzung und verfahren zu ihrer anwendung
WO2009035253A3 (en) Novel use of scoparone
WO2007071840A3 (fr) Composes a base de quatre cycles aromatiques, preparation et utilisations
JO2666B1 (en) Use of agomelatine for medications to treat bilateral mental disorders

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: SK BIOPHARMACEUTICALS CO., LTD. (KR)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/04/2006, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/04/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF